Telavancin user fee deadline passes without FDA action
This article was originally published in Scrip
Executive Summary
The user fee deadline for Theravance's antibiotic telavancin has passed without a US regulatory decision as the FDAapparently continues its investigation into the conduct of the pivotal Phase III trials.